AI-generated analysis. Always verify with the original filing.
On February 17, 2026, Atossa Therapeutics, Inc. received a letter from Nasdaq confirming it regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive trading days as of February 13, 2026. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.